Natural History Study of Children With Metachromatic Leukodystrophy

This study has been terminated.
(Enrollment issues)
Sponsor:
Information provided by (Responsible Party):
Shire
ClinicalTrials.gov Identifier:
NCT01963650
First received: October 11, 2013
Last updated: April 19, 2016
Last verified: April 2016
  Purpose
The purpose of this study is evaluate the natural course of disease progression related to gross motor function in children with metachromatic leukodystrophy (MLD).

Condition
Lipid Metabolism Disorders
Metachromatic Leukodystrophy (MLD)
Nervous System Diseases
Brain Diseases
Central Nervous System Diseases
Demyelinating Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Sphingolipidoses
Hereditary Central Nervous System Demyelinating Diseases
Metabolic Inborn Brain Diseases
Lysosomal Storage Diseases
Metabolic Diseases
Sulfatidosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Natural History Study of Children With Metachromatic Leukodystrophy

Resource links provided by NLM:


Further study details as provided by Shire:

Primary Outcome Measures:
  • The primary endpoint of this study is the change from baseline in motor function using the GMFM-88 total (percent) score. [ Time Frame: Week 0 to Week 104 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The change from baseline in ability to swallow as assessed by the Functional Endoscopic Evaluation of Swallowing. [ Time Frame: Week 0 to Week 104 ] [ Designated as safety issue: No ]
  • The change from baseline in nerve conduction as measured by the electroneurography. [ Time Frame: Week 0 to Week 104 ] [ Designated as safety issue: No ]
  • The change from baseline in the adaptive behavior composite standard score as measured by the Vineland Adaptive Behavior Scales. [ Time Frame: Week 0 to Week 104 ] [ Designated as safety issue: No ]
  • The change from baseline in domain-specific Caregiver Observed MLD Functioning and Outcomes Reporting Tool. [ Time Frame: Week 0 to Week 104 ] [ Designated as safety issue: No ]
  • The change from baseline in cognitive function using the Mullen Scales of Early Learning. [ Time Frame: Week 0 to Week 104 ] [ Designated as safety issue: No ]
  • Reporting of any study procedure-related nonserious AEs and/or any SAEs [ Time Frame: Week 0 to Week 114 ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples With DNA
Sample for genotype testing is collected and any remaining sample is retained for follow up or repeat testing. The sample is not retained for unspecified additional testing.

Enrollment: 1
Study Start Date: December 2013
Study Completion Date: March 2016
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
No treatment

Detailed Description:

Metachromatic leukodystrophy (MLD) is an inherited, autosomal recessive disorder of lipid metabolism characterized by deficient activity of the lysosomal enzyme, arylsulfatase A (ASA). MLD is a rare genetic disease that occurs in most parts of the world. The estimated overall incidence of the disease in the western world is approximately 1 in 100,000 live births.

This study is a multicenter, observational, longitudinal study that plans to enroll up to 30 patients with onset of MLD-related signs and symptoms prior to 30 months of age and who are less than 12 years of age. Patients will participate in this study for approximately 114 weeks (Screening through Follow-up) and will be assessed at defined intervals for disease status.

  Eligibility

Ages Eligible for Study:   up to 12 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study will enroll up to 30 male or female children (<12 years of age) with a confirmed MLD diagnosis.
Criteria

Inclusion Criteria:

  1. Confirmed diagnosis of MLD by both:

    • arylsulfatase A (ASA) deficiency by assay in leukocytes AND
    • elevated sulfatide in urine
  2. Appearance of the first symptoms of disease at or before 30 months of age.
  3. A GMFM-88 total (percent) score greater than or equal to 40 at the screening examination.
  4. The patient is less than 12 years of age at the time of enrollment.
  5. The patient and his/her parent or legally authorized representative(s) must have the ability to comply with the clinical protocol.
  6. Patient's parent or legally authorized representative(s) must provide written informed consent prior to performing any study-related activities. Study-related activities are any procedures that would not have been performed during normal management of the patient.

Exclusion Criteria:

  1. History of hematopoietic stem cell transplantation.
  2. The patient has any known or suspected hypersensitivity to agents used for anesthesia or is thought to be at an unacceptably high risk for associated potential complications of airway compromise or other conditions.
  3. Any other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the study.
  4. The patient is enrolled in another clinical study that involves the use of any investigational product (drug or device) within 30 days prior to study enrollment or at any time during the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01963650

Locations
United States, California
Harbor UCLA Pediatrics
Torrance, California, United States, 90502
United States, District of Columbia
Children's National Health System
Washington, District of Columbia, United States, 20010
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
United States, Pennsylvania
Children's Hospital Of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15224
Argentina
Hospital Universitario Austral
Pilar, Argentina, B1629ODT
Belgium
Universitair Ziekenhuis Antwerpen (UZA) (University Hospital Antwerpen)
Edegem, Belgium, 2650
Brazil
Hospital de Cllnicas de Porto Alegre (HCPA) / UFRGS
Porto Alegre, Brazil, 90035-003
Canada
Montreal Children's Hospital
Westmount, Canada, H3Z 2Z3
Denmark
Copenhagen University Hospital, Rigshospitalet
Copenhagen, Denmark, 2100
France
Hôpital De Bicêtre
Le Kremlin Bicêtre, France, 94275
Germany
Univesitatsklinikum Tubingen Klinik fur Kinder und Jugendmedizin
Tubingen, Germany, 72076
Japan
Faculty Of Medicine, Osaka University Graduate School Of Medicine
Osaka, Japan, 565-0871
The Jikei University School Of Medicine - Institute Of Dna Medicine
Tokyo, Japan, 105-8461
Turkey
Hacettepe Universitesi Tip Fakultesi Onkoloji Hastanesi
Ankara, Turkey, 6100
Sponsors and Collaborators
Shire
Investigators
Study Director: Margaret Wasilewski, MD Shire
  More Information

Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01963650     History of Changes
Other Study ID Numbers: HGT-MLD-092 
Study First Received: October 11, 2013
Last Updated: April 19, 2016
Health Authority: France: Ethics Committee
Argentina: National Committee of Ethics in Science and Technology
Denmark: Ethics Committee
Brazil: Ministry of Health
United States: Institutional Review Board
Belgium: Institutional Review Board
Germany: Ethics Commission
Turkey: Ethics Committee
Canada: Ethics Review Committee
Japan: Japanese Pharmaceuticals and Medical Devices Agency

Additional relevant MeSH terms:
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Brain Diseases
Central Nervous System Diseases
Demyelinating Diseases
Genetic Diseases, Inborn
Hereditary Central Nervous System Demyelinating Diseases
Leukodystrophy, Metachromatic
Lipid Metabolism Disorders
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases
Sphingolipidoses
Sulfatidosis
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Heredodegenerative Disorders, Nervous System
Leukoencephalopathies
Lipid Metabolism, Inborn Errors
Lipidoses
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on May 26, 2016